FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox

Under a relatively-high magnification of 1125X, processed using Gutstein's methyl violet staining method, this smallpox smear from a skin lesion of a smallpox patient, revealed the presence of numerous viral particles, or elementary bodies (EBs), throughout the sample, which stain light to dark violet. Gutstein’s method is a simple and quick procedure that allows for the analysis of samples extracted from early papulovesicular skin lesions, in order to determine the presence of EBs that could provide a provisional diagnosis. However, it must be kept in mind that a negative finding is of little importance. In comparative terms, EBs measure approximately 1/4th to 1/5th the size of a staphylococci bacterium. Source: CDC

The Food and Drug Administration (FDA) announces the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.

“Following the global Smallpox Eradication Program, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. Routine vaccination of the American public was stopped in 1972 after the disease was eradicated in the U.S. and, as a result, a large proportion of the U.S., as well as the global population has no immunity,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research. “Therefore, although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect. Today’s approval reflects the U.S. government’s commitment to preparedness through support for the development of safe and effective vaccines, therapeutics, and other medical countermeasures.”

Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.

Smallpox, which is caused by the variola virus, emerged in human populations thousands of years ago and is a highly contagious and often fatal infectious disease. A person infected with smallpox typically develops a rash characterized by raised pocks on the face and body. The smallpox virus is spread through saliva and droplets from the respiratory tract or by direct or indirect contact with the virus as it is shed from skin lesions. The virus can also be spread through other body fluids and contaminated clothing or bed linen. If a person is infected with smallpox and they are in close contact with others, the virus can spread quickly.

Monkeypox, which does not occur naturally in the U.S., is a rare disease caused by infection with monkeypox virus, which causes symptoms similar to, but milder than, smallpox. Monkeypox begins with fever, headache, muscle aches and exhaustion and can be fatal, even though it is typically milder than smallpox. It is transmitted to people from various wild animals, such as rodents and primates. In 2003, the U.S. experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa.

Jynneos does not contain the viruses that cause smallpox or monkeypox. It is made from a vaccinia virus, a virus that is closely related to, but less harmful than, variola or monkeypox viruses and can protect against both of these diseases. Jynneos contains a modified form of the vaccinia virus called Modified Vaccinia Ankara, which does not cause disease in humans and is non-replicating, meaning it cannot reproduce in human cells.

The effectiveness of Jynneos for the prevention of smallpox was determined in a clinical study comparing the immune responses in study participants who received either Jynneos or ACAM2000, an FDA-approved vaccine for the prevention of smallpox. The study included approximately 400 healthy adults, 18 through 42 years of age who had never been vaccinated for smallpox, in which half of the study participants received two doses of Jynneos administered 28 days apart, and half received one dose of ACAM2000. The group vaccinated with Jynneos had an immune response that was not inferior to immune responses to ACAM2000. Vaccine effectiveness for the prevention of smallpox was also inferred from supportive animal studies that showed prior vaccination with Jynneos protected non-human primates who were exposed to viruses related to the smallpox virus.

The effectiveness of Jynneos for the prevention of monkeypox disease is inferred from the antibody responses in the smallpox clinical study participants and from studies in non-human primates that showed protection of animals vaccinated with Jynneos who were exposed to the monkeypox virus.

The safety of Jynneos was assessed in more than 7,800 individuals who received at least one dose of the vaccine. The most commonly reported side effects were pain, redness, swelling, itching, firmness at the injection site, muscle pain, headache and fatigue. No safety concerns that would require a Medication Guide have been identified for Jynneos. Jynneos is administered in two doses given four weeks apart.

The FDA granted the approval of Jynneos to Bavarian Nordic A/S. The FDA granted the application Priority Review and with this approval, the FDA issued a material threat medical countermeasure (MCM) priority review voucher to Bavarian Nordic A/S. The Federal Food, Drug, and Cosmetic Act, as amended by the 21st Century Cures (Cures) Act, authorizes the FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria.

Source: FDA

 

16 Comments on "FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox"

  1. 927480 92640Some truly good and utilitarian information on this internet web site , also I believe the style and design holds excellent attributes. 937059

  2. There’s noticeably a bundle to find out about this. I assume you made sure nice points in features also….

  3. 211561 446801hey, your internet web site is outstanding. We do appreciate your work 426713

  4. Very good suggestions, you just gained a brand new reader. Im curious if you have any follow ups to this post?

  5. Starting a website kind of like this one forced me to do some research and I found your post to be quite helpful. My content is centered around the idea of knowledge, fun and sharing. I wish you fine luck with your web site in the future and you can be sure I’ll be following it.

  6. I think that is an fascinating point, it made me think a bit. Thanks for sparking my thinking cap. Sometimes I get so much in a rut that I just believe like a record.

  7. You have actually created some exceptional points here. I specifically appreciate the way you’ve been able to stick so much thought into a relatively short post (comparitively) which creates it an thoughtful publish on your subject. In my opinion, you’ve presented the topic in a quite thorough yet concise manner, that is genuinely useful when somebody wants to get the facts without spending too a lot time searching the web and sifting out the noise to discover the answers to their questions. I usually get so frustrated with so plentiful in the final results inside the major SE’s due to the fact they normally seem to mostly be filled with filler content that often isn’t extremely sensible. If you don’t mind I’m going to add this post and your webpage to my delicious favorites so I can share it with my family. I appear forward to approaching back to read your future posts as well.

  8. Trzeba mieć wytrwałość i wiarę we własne siły Twój portal jest tego przykładem. Trzeba wierzyć, że człowiek jest do czegos zdolny i osiągnać to za wszelka cenę!.

  9. I admire the valuable information you offer inside your content. I will bookmark your weblog and also have my youngsters test up right here often. Im fairly sure theyll learn a lot of new stuff here than anyone else!

  10. Great, thanks for sharing this blog post.Really looking forward to read more. Really Great.

  11. This is a appealing article by the way. I am going to go ahead and save this article for my sister to read later on tomorrow. Keep up the superior work.

  12. Awesome and an highly interesting post to stumble at on this massive website! Never write some replies only now i couldnt i could not resist ..

  13. Resources such as the one you mentioned here will be extremely helpful to myself! I will publish a hyperlink to this page on my personal blog. I am certain my site visitors will uncover that fairly valuable. Have you considered promoting your blog? add it to SEO Directory right now 🙂 http://www.links.m106.com

  14. hello anyone, I was just checkin out this blog and I really admire the basis of the article, and have nothing to do, so if anyone would like to to have an interesting conversation about it, please contact me on AIM, my name is rick smith

  15. 136526 472999Hi, Neat post. Theres a problem together with your web site in internet explorer, would test this IE nonetheless could be the market leader and a big portion of individuals will miss your amazing writing because of this dilemma. 180790

  16. 413361 159279This put up is totaly unrelated to what I used to be seeking google for, even so it was indexed on the first page. I guess your doing something appropriate if Google likes you adequate to spot you at the first page of a non related search. 864913

Leave a comment

Your email address will not be published.


*